MARATTO

preprint · Qeios

Sputum Interleukin-32 in childhood asthma: correlation with IL-1β

Abstract

_Background:_ Asthma is an airway disorder where inflammatory cytokines are partly responsible for exacerbating the disease. Interleukin (IL)-32, generally referred to as natural killer cell (NK4) transcript 4, is described as an immunoregulator involved in the stimulation of anti-/pro-inflammatory cytokines. The abnormal presence of IL-32 has been observed during inflammatory diseases, particularly in asthma. This study aims to characterize IL-32 in the inflammatory process in patients with severe asthma. _Methods:_ IL-32 and IL-1β levels in the supernatant of induced sputum obtained from 59 asthma patients (mild: 20 patients; moderate: 20 patients; severe: 19 patients) were measured using ELISA. Sputum IL-32 mRNA expression was measured by RT- PCR. _Results:_ Sputum IL-32 was significantly elevated at the protein (_p= 0.00019_) and mRNA expression (_p < 0.0001_) in asthmatics compared to non-asthmatic controls. IL-32 was elevated in severe asthmatic patients (_p < 0.0001_) compared to mild-moderate asthma. Severe asthmatics allergic to house dust mites expressed higher sputum IL-32 level than severe asthmatics without allergy (_p = 0.0001_). A significant association was found between sputum IL-32 and IL-32 mRNA (r =0.531_; p = 0.0159_) in severe asthma. In the same way, sputum IL-1β and IL-32 were significantly correlated (r = 0.476; _p = 0.0337_). _Conclusion:_ The level of IL-32 in induced sputum may be associated with asthma severity.

Research topics

  • Asthma and respiratory diseases
  • Dermatology and Skin Diseases
  • IL-33, ST2, and ILC Pathways

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.32388/7kki09.2

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.